Ontology type: schema:ScholarlyArticle
2018-01-19
AUTHORSR. De Vecchis, C. Ariano, G. Di Biase, M. Noutsias
ABSTRACTBackgroundThe combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class II–IV.MethodsOur retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a beta-blocker and mineral receptor antagonist (MRA) in a group of HFREF patients with NYHA class II–III HF vs. conventional therapy (ACE inhibitor or angiotensin II receptor blocker added to a beta-blocker plus an MRA) administered to a control group of HFREF patients with comparable clinical features. In both groups, treatment was supplemented by a loop diuretic, usually furosemide, at variable doses. The primary outcomes were all-cause death and HF hospitalizations. Safety outcomes were symptomatic hypotension, angioedema, hyperkalemia, and worsening renal function.ResultsMortality at 6 months was 6.8% in patients taking sacubitril/valsartan vs. 34% in those on conventional therapy (odds ratio [OR] = 0.14; 95% CI: 0.04–0.49). Moreover, there was a 4.5% rate of HF hospitalizations in the sacubitril/valsartan group vs. 59% in the control group (OR = 0.03; 95% CI: 0.01–0.14). Safety outcomes were comparable in the two groups, although hypotension (systolic blood pressure < 100 mm Hg) was found in 15.9% of patients in the sacubitril/valsartan group vs. 5.7% in the control group (OR = 3.14; 95% CI: 0.94–10.55).ConclusionSacubitril/valsartan offered strong protection against all-cause death and HF hospitalizations at 6 months without any significant side effects. To validate this efficacious molecule, further postmarketing observational studies, focusing mainly on hypotension and angioedema are warranted. More... »
PAGES425-432
http://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1
DOIhttp://dx.doi.org/10.1007/s00059-017-4671-1
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1100478773
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/29350254
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aminobutyrates",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antihypertensive Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Combinations",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Heart Failure",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neprilysin",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Stroke Volume",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tetrazoles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Valsartan",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Preventive Cardiology and Rehabilitation Unit, DSB 29 \u201cS.\u00a0Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Preventive Cardiology and Rehabilitation Unit, DSB 29 \u201cS.\u00a0Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy"
],
"type": "Organization"
},
"familyName": "De Vecchis",
"givenName": "R.",
"id": "sg:person.0704361014.79",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Geriatrics, Casa di Cura \u201cSollievo della Sofferenza\u201d, viale Cappuccini\u00a02, 71013, San Giovanni Rotondo, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Preventive Cardiology and Rehabilitation Unit, DSB 29 \u201cS.\u00a0Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy",
"Division of Geriatrics, Casa di Cura \u201cSollievo della Sofferenza\u201d, viale Cappuccini\u00a02, 71013, San Giovanni Rotondo, Italy"
],
"type": "Organization"
},
"familyName": "Ariano",
"givenName": "C.",
"id": "sg:person.0660263343.51",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Geriatrics, Clinic \u201cS. Maria del Pozzo\u201d, via Pomigliano\u00a040, 80049, Somma Vesuviana, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Division of Geriatrics, Clinic \u201cS. Maria del Pozzo\u201d, via Pomigliano\u00a040, 80049, Somma Vesuviana, Italy"
],
"type": "Organization"
},
"familyName": "Di Biase",
"givenName": "G.",
"id": "sg:person.01066703417.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066703417.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Stra\u00dfe\u00a040, 06120, Halle, Germany",
"id": "http://www.grid.ac/institutes/grid.461820.9",
"name": [
"Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Stra\u00dfe\u00a040, 06120, Halle, Germany"
],
"type": "Organization"
},
"familyName": "Noutsias",
"givenName": "M.",
"id": "sg:person.01077606445.25",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077606445.25"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00059-017-4626-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1091896405",
"https://doi.org/10.1007/s00059-017-4626-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s11897-017-0327-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1084033357",
"https://doi.org/10.1007/s11897-017-0327-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/164_2016_77",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000389269",
"https://doi.org/10.1007/164_2016_77"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00059-013-3772-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047353802",
"https://doi.org/10.1007/s00059-013-3772-8"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-01-19",
"datePublishedReg": "2018-01-19",
"description": "BackgroundThe combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class\u00a0II\u2013IV.MethodsOur retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a\u00a0beta-blocker and mineral receptor antagonist (MRA) in a\u00a0group of HFREF patients with NYHA class\u00a0II\u2013III HF vs. conventional therapy (ACE inhibitor or angiotensin\u00a0II receptor blocker added to a beta-blocker plus an\u00a0MRA) administered to a\u00a0control group of HFREF patients with comparable clinical features. In both groups, treatment was supplemented by a\u00a0loop diuretic, usually furosemide, at variable doses. The primary outcomes were all-cause death and HF hospitalizations. Safety outcomes were symptomatic hypotension, angioedema, hyperkalemia, and worsening renal function.ResultsMortality at 6\u00a0months was 6.8% in patients taking sacubitril/valsartan vs. 34% in those on conventional therapy (odds ratio [OR]\u00a0= 0.14; 95% CI: 0.04\u20130.49). Moreover, there was a 4.5% rate of HF hospitalizations in the sacubitril/valsartan group vs. 59% in the control group (OR\u00a0= 0.03; 95% CI: 0.01\u20130.14). Safety outcomes were comparable in the two groups, although hypotension (systolic blood pressure <\u202f100\u2009mm\u00a0Hg) was found in 15.9% of patients in the sacubitril/valsartan group vs. 5.7% in the control group (OR\u00a0= 3.14; 95% CI: 0.94\u201310.55).ConclusionSacubitril/valsartan offered strong protection against all-cause death and HF hospitalizations at 6\u00a0months without any significant side effects. To validate this efficacious molecule, further postmarketing observational studies, focusing mainly on hypotension and angioedema are warranted.",
"genre": "article",
"id": "sg:pub.10.1007/s00059-017-4671-1",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1087175",
"issn": [
"0340-9937",
"1615-6692"
],
"name": "Herz",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "5",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "44"
}
],
"keywords": [
"sacubitril/valsartan",
"sacubitril/valsartan group",
"left ventricular ejection fraction",
"ventricular ejection fraction",
"HF hospitalization",
"control group",
"HFrEF patients",
"cause death",
"NYHA class",
"valsartan group",
"ejection fraction",
"conventional therapy",
"safety outcomes",
"reduced left ventricular ejection fraction",
"heart failure hospitalization",
"retrospective cohort study",
"comparable clinical features",
"significant side effects",
"failure hospitalization",
"symptomatic hypotension",
"renal function",
"cardiovascular mortality",
"cohort study",
"primary outcome",
"heart failure",
"clinical features",
"loop diuretics",
"cardiac insufficiency",
"receptor antagonist",
"observational study",
"side effects",
"hospitalization",
"patients",
"hypotension",
"valsartan",
"variable doses",
"efficacious molecules",
"angioedema",
"death",
"therapy",
"outcomes",
"months",
"group",
"enalapril",
"diuretics",
"hyperkalemia",
"ResultsMortality",
"strong protection",
"insufficiency",
"antagonist",
"mortality",
"doses",
"treatment",
"study",
"effect",
"failure",
"fraction",
"rate",
"protection",
"function",
"addition",
"features",
"HF",
"molecules",
"class"
],
"name": "Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction",
"pagination": "425-432",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1100478773"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00059-017-4671-1"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"29350254"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00059-017-4671-1",
"https://app.dimensions.ai/details/publication/pub.1100478773"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:34",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_771.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00059-017-4671-1"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'
This table displays all metadata directly associated to this object as RDF triples.
219 TRIPLES
22 PREDICATES
107 URIs
95 LITERALS
19 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s00059-017-4671-1 | schema:about | N15fe2669b1314f8b8ce08e97112ae895 |
2 | ″ | ″ | N26c3d2648adc4529869c784ad6f47126 |
3 | ″ | ″ | N2a5698057201438e914b970d7e4accbd |
4 | ″ | ″ | N6fe8983da46d4e138fbc3224a835ac38 |
5 | ″ | ″ | N71c36a8ed1cc4ef1ae2869667ddda00f |
6 | ″ | ″ | N752d2645c9034be6b91f0cf2b34f8cb6 |
7 | ″ | ″ | N756f63793b7141ad89a1d82ae4591319 |
8 | ″ | ″ | Na4277db2796a46deb03c3eba012691d1 |
9 | ″ | ″ | Nd7bfa45ec60c406c96052e2d92c33d62 |
10 | ″ | ″ | Ne6cfc0ed27604abbb1fa6a11d8568a09 |
11 | ″ | ″ | Nf30cd4412943401a8aead37f08abe1ee |
12 | ″ | ″ | Nfabb47e94a5247988868bdb40cddb3ae |
13 | ″ | ″ | anzsrc-for:11 |
14 | ″ | ″ | anzsrc-for:1102 |
15 | ″ | schema:author | Ne81911e9f91a457289cdc82cb7a185a0 |
16 | ″ | schema:citation | sg:pub.10.1007/164_2016_77 |
17 | ″ | ″ | sg:pub.10.1007/s00059-013-3772-8 |
18 | ″ | ″ | sg:pub.10.1007/s00059-017-4626-6 |
19 | ″ | ″ | sg:pub.10.1007/s11897-017-0327-y |
20 | ″ | schema:datePublished | 2018-01-19 |
21 | ″ | schema:datePublishedReg | 2018-01-19 |
22 | ″ | schema:description | BackgroundThe combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class II–IV.MethodsOur retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a beta-blocker and mineral receptor antagonist (MRA) in a group of HFREF patients with NYHA class II–III HF vs. conventional therapy (ACE inhibitor or angiotensin II receptor blocker added to a beta-blocker plus an MRA) administered to a control group of HFREF patients with comparable clinical features. In both groups, treatment was supplemented by a loop diuretic, usually furosemide, at variable doses. The primary outcomes were all-cause death and HF hospitalizations. Safety outcomes were symptomatic hypotension, angioedema, hyperkalemia, and worsening renal function.ResultsMortality at 6 months was 6.8% in patients taking sacubitril/valsartan vs. 34% in those on conventional therapy (odds ratio [OR] = 0.14; 95% CI: 0.04–0.49). Moreover, there was a 4.5% rate of HF hospitalizations in the sacubitril/valsartan group vs. 59% in the control group (OR = 0.03; 95% CI: 0.01–0.14). Safety outcomes were comparable in the two groups, although hypotension (systolic blood pressure < 100 mm Hg) was found in 15.9% of patients in the sacubitril/valsartan group vs. 5.7% in the control group (OR = 3.14; 95% CI: 0.94–10.55).ConclusionSacubitril/valsartan offered strong protection against all-cause death and HF hospitalizations at 6 months without any significant side effects. To validate this efficacious molecule, further postmarketing observational studies, focusing mainly on hypotension and angioedema are warranted. |
23 | ″ | schema:genre | article |
24 | ″ | schema:inLanguage | en |
25 | ″ | schema:isAccessibleForFree | false |
26 | ″ | schema:isPartOf | N773326eceaf84637ad6b2407fa506305 |
27 | ″ | ″ | Nac100509b7f34479b705985ea3e0dfe1 |
28 | ″ | ″ | sg:journal.1087175 |
29 | ″ | schema:keywords | HF |
30 | ″ | ″ | HF hospitalization |
31 | ″ | ″ | HFrEF patients |
32 | ″ | ″ | NYHA class |
33 | ″ | ″ | ResultsMortality |
34 | ″ | ″ | addition |
35 | ″ | ″ | angioedema |
36 | ″ | ″ | antagonist |
37 | ″ | ″ | cardiac insufficiency |
38 | ″ | ″ | cardiovascular mortality |
39 | ″ | ″ | cause death |
40 | ″ | ″ | class |
41 | ″ | ″ | clinical features |
42 | ″ | ″ | cohort study |
43 | ″ | ″ | comparable clinical features |
44 | ″ | ″ | control group |
45 | ″ | ″ | conventional therapy |
46 | ″ | ″ | death |
47 | ″ | ″ | diuretics |
48 | ″ | ″ | doses |
49 | ″ | ″ | effect |
50 | ″ | ″ | efficacious molecules |
51 | ″ | ″ | ejection fraction |
52 | ″ | ″ | enalapril |
53 | ″ | ″ | failure |
54 | ″ | ″ | failure hospitalization |
55 | ″ | ″ | features |
56 | ″ | ″ | fraction |
57 | ″ | ″ | function |
58 | ″ | ″ | group |
59 | ″ | ″ | heart failure |
60 | ″ | ″ | heart failure hospitalization |
61 | ″ | ″ | hospitalization |
62 | ″ | ″ | hyperkalemia |
63 | ″ | ″ | hypotension |
64 | ″ | ″ | insufficiency |
65 | ″ | ″ | left ventricular ejection fraction |
66 | ″ | ″ | loop diuretics |
67 | ″ | ″ | molecules |
68 | ″ | ″ | months |
69 | ″ | ″ | mortality |
70 | ″ | ″ | observational study |
71 | ″ | ″ | outcomes |
72 | ″ | ″ | patients |
73 | ″ | ″ | primary outcome |
74 | ″ | ″ | protection |
75 | ″ | ″ | rate |
76 | ″ | ″ | receptor antagonist |
77 | ″ | ″ | reduced left ventricular ejection fraction |
78 | ″ | ″ | renal function |
79 | ″ | ″ | retrospective cohort study |
80 | ″ | ″ | sacubitril/valsartan |
81 | ″ | ″ | sacubitril/valsartan group |
82 | ″ | ″ | safety outcomes |
83 | ″ | ″ | side effects |
84 | ″ | ″ | significant side effects |
85 | ″ | ″ | strong protection |
86 | ″ | ″ | study |
87 | ″ | ″ | symptomatic hypotension |
88 | ″ | ″ | therapy |
89 | ″ | ″ | treatment |
90 | ″ | ″ | valsartan |
91 | ″ | ″ | valsartan group |
92 | ″ | ″ | variable doses |
93 | ″ | ″ | ventricular ejection fraction |
94 | ″ | schema:name | Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction |
95 | ″ | schema:pagination | 425-432 |
96 | ″ | schema:productId | N11d1bb5c799d429285f5adcf340f56bd |
97 | ″ | ″ | N463ed00f12664c02ac5d39c5831458bb |
98 | ″ | ″ | N91478364fecd490faba6a2c29a39b897 |
99 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1100478773 |
100 | ″ | ″ | https://doi.org/10.1007/s00059-017-4671-1 |
101 | ″ | schema:sdDatePublished | 2022-05-20T07:34 |
102 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
103 | ″ | schema:sdPublisher | N4fdbec30cdd94fba8a2503fa52378037 |
104 | ″ | schema:url | https://doi.org/10.1007/s00059-017-4671-1 |
105 | ″ | sgo:license | sg:explorer/license/ |
106 | ″ | sgo:sdDataset | articles |
107 | ″ | rdf:type | schema:ScholarlyArticle |
108 | N11d1bb5c799d429285f5adcf340f56bd | schema:name | dimensions_id |
109 | ″ | schema:value | pub.1100478773 |
110 | ″ | rdf:type | schema:PropertyValue |
111 | N15fe2669b1314f8b8ce08e97112ae895 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
112 | ″ | schema:name | Neprilysin |
113 | ″ | rdf:type | schema:DefinedTerm |
114 | N26c3d2648adc4529869c784ad6f47126 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
115 | ″ | schema:name | Male |
116 | ″ | rdf:type | schema:DefinedTerm |
117 | N2a5698057201438e914b970d7e4accbd | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
118 | ″ | schema:name | Treatment Outcome |
119 | ″ | rdf:type | schema:DefinedTerm |
120 | N463ed00f12664c02ac5d39c5831458bb | schema:name | doi |
121 | ″ | schema:value | 10.1007/s00059-017-4671-1 |
122 | ″ | rdf:type | schema:PropertyValue |
123 | N4fdbec30cdd94fba8a2503fa52378037 | schema:name | Springer Nature - SN SciGraph project |
124 | ″ | rdf:type | schema:Organization |
125 | N6fe8983da46d4e138fbc3224a835ac38 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
126 | ″ | schema:name | Humans |
127 | ″ | rdf:type | schema:DefinedTerm |
128 | N71c36a8ed1cc4ef1ae2869667ddda00f | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
129 | ″ | schema:name | Drug Combinations |
130 | ″ | rdf:type | schema:DefinedTerm |
131 | N752d2645c9034be6b91f0cf2b34f8cb6 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
132 | ″ | schema:name | Tetrazoles |
133 | ″ | rdf:type | schema:DefinedTerm |
134 | N756f63793b7141ad89a1d82ae4591319 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
135 | ″ | schema:name | Antihypertensive Agents |
136 | ″ | rdf:type | schema:DefinedTerm |
137 | N773326eceaf84637ad6b2407fa506305 | schema:volumeNumber | 44 |
138 | ″ | rdf:type | schema:PublicationVolume |
139 | N91478364fecd490faba6a2c29a39b897 | schema:name | pubmed_id |
140 | ″ | schema:value | 29350254 |
141 | ″ | rdf:type | schema:PropertyValue |
142 | N9a85763966fd4bbea94eb6df68682984 | rdf:first | sg:person.0660263343.51 |
143 | ″ | rdf:rest | Nfead12ef42684139befc6c790beea67e |
144 | Na4277db2796a46deb03c3eba012691d1 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
145 | ″ | schema:name | Retrospective Studies |
146 | ″ | rdf:type | schema:DefinedTerm |
147 | Nac100509b7f34479b705985ea3e0dfe1 | schema:issueNumber | 5 |
148 | ″ | rdf:type | schema:PublicationIssue |
149 | Nc95b77208ab44c558a45b32f9e6de0f9 | rdf:first | sg:person.01077606445.25 |
150 | ″ | rdf:rest | rdf:nil |
151 | Nd7bfa45ec60c406c96052e2d92c33d62 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
152 | ″ | schema:name | Aminobutyrates |
153 | ″ | rdf:type | schema:DefinedTerm |
154 | Ne6cfc0ed27604abbb1fa6a11d8568a09 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
155 | ″ | schema:name | Stroke Volume |
156 | ″ | rdf:type | schema:DefinedTerm |
157 | Ne81911e9f91a457289cdc82cb7a185a0 | rdf:first | sg:person.0704361014.79 |
158 | ″ | rdf:rest | N9a85763966fd4bbea94eb6df68682984 |
159 | Nf30cd4412943401a8aead37f08abe1ee | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
160 | ″ | schema:name | Heart Failure |
161 | ″ | rdf:type | schema:DefinedTerm |
162 | Nfabb47e94a5247988868bdb40cddb3ae | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
163 | ″ | schema:name | Valsartan |
164 | ″ | rdf:type | schema:DefinedTerm |
165 | Nfead12ef42684139befc6c790beea67e | rdf:first | sg:person.01066703417.19 |
166 | ″ | rdf:rest | Nc95b77208ab44c558a45b32f9e6de0f9 |
167 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
168 | ″ | schema:name | Medical and Health Sciences |
169 | ″ | rdf:type | schema:DefinedTerm |
170 | anzsrc-for:1102 | schema:inDefinedTermSet | anzsrc-for: |
171 | ″ | schema:name | Cardiorespiratory Medicine and Haematology |
172 | ″ | rdf:type | schema:DefinedTerm |
173 | sg:journal.1087175 | schema:issn | 0340-9937 |
174 | ″ | ″ | 1615-6692 |
175 | ″ | schema:name | Herz |
176 | ″ | schema:publisher | Springer Nature |
177 | ″ | rdf:type | schema:Periodical |
178 | sg:person.01066703417.19 | schema:affiliation | grid-institutes:None |
179 | ″ | schema:familyName | Di Biase |
180 | ″ | schema:givenName | G. |
181 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066703417.19 |
182 | ″ | rdf:type | schema:Person |
183 | sg:person.01077606445.25 | schema:affiliation | grid-institutes:grid.461820.9 |
184 | ″ | schema:familyName | Noutsias |
185 | ″ | schema:givenName | M. |
186 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077606445.25 |
187 | ″ | rdf:type | schema:Person |
188 | sg:person.0660263343.51 | schema:affiliation | grid-institutes:None |
189 | ″ | schema:familyName | Ariano |
190 | ″ | schema:givenName | C. |
191 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51 |
192 | ″ | rdf:type | schema:Person |
193 | sg:person.0704361014.79 | schema:affiliation | grid-institutes:None |
194 | ″ | schema:familyName | De Vecchis |
195 | ″ | schema:givenName | R. |
196 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79 |
197 | ″ | rdf:type | schema:Person |
198 | sg:pub.10.1007/164_2016_77 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1000389269 |
199 | ″ | ″ | https://doi.org/10.1007/164_2016_77 |
200 | ″ | rdf:type | schema:CreativeWork |
201 | sg:pub.10.1007/s00059-013-3772-8 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1047353802 |
202 | ″ | ″ | https://doi.org/10.1007/s00059-013-3772-8 |
203 | ″ | rdf:type | schema:CreativeWork |
204 | sg:pub.10.1007/s00059-017-4626-6 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1091896405 |
205 | ″ | ″ | https://doi.org/10.1007/s00059-017-4626-6 |
206 | ″ | rdf:type | schema:CreativeWork |
207 | sg:pub.10.1007/s11897-017-0327-y | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1084033357 |
208 | ″ | ″ | https://doi.org/10.1007/s11897-017-0327-y |
209 | ″ | rdf:type | schema:CreativeWork |
210 | grid-institutes:None | schema:alternateName | Division of Geriatrics, Casa di Cura “Sollievo della Sofferenza”, viale Cappuccini 2, 71013, San Giovanni Rotondo, Italy |
211 | ″ | ″ | Division of Geriatrics, Clinic “S. Maria del Pozzo”, via Pomigliano 40, 80049, Somma Vesuviana, Italy |
212 | ″ | ″ | Preventive Cardiology and Rehabilitation Unit, DSB 29 “S. Gennaro dei Poveri Hospital”, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy |
213 | ″ | schema:name | Division of Geriatrics, Casa di Cura “Sollievo della Sofferenza”, viale Cappuccini 2, 71013, San Giovanni Rotondo, Italy |
214 | ″ | ″ | Division of Geriatrics, Clinic “S. Maria del Pozzo”, via Pomigliano 40, 80049, Somma Vesuviana, Italy |
215 | ″ | ″ | Preventive Cardiology and Rehabilitation Unit, DSB 29 “S. Gennaro dei Poveri Hospital”, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy |
216 | ″ | rdf:type | schema:Organization |
217 | grid-institutes:grid.461820.9 | schema:alternateName | Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Straße 40, 06120, Halle, Germany |
218 | ″ | schema:name | Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Straße 40, 06120, Halle, Germany |
219 | ″ | rdf:type | schema:Organization |